Diadema Partners LP Makes New $351,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Diadema Partners LP purchased a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 4th quarter, Holdings Channel reports. The fund purchased 42,081 shares of the company’s stock, valued at approximately $351,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Zevra Therapeutics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock valued at $23,554,000 after acquiring an additional 68,151 shares during the last quarter. Altium Capital Management LLC raised its stake in shares of Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock valued at $15,429,000 after purchasing an additional 150,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Zevra Therapeutics by 13.8% during the fourth quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company’s stock worth $9,912,000 after purchasing an additional 144,256 shares during the last quarter. AIGH Capital Management LLC bought a new position in Zevra Therapeutics in the fourth quarter worth about $6,577,000. Finally, State Street Corp boosted its holdings in shares of Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John B. Bode purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at approximately $318,400. The trade was a 33.33 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ZVRA shares. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Guggenheim upped their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $22.29.

Zevra Therapeutics Stock Down 3.9 %

ZVRA stock opened at $6.87 on Tuesday. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The business has a 50 day moving average of $7.58 and a 200 day moving average of $8.15. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market cap of $371.78 million, a PE ratio of -3.49 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. On average, research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.